Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAI-TGF-alpha

Drug Profile

SAI-TGF-alpha

Alternative Names: Cancer vaccine TGF-alpha - Micromet; TGF-alpha cancer vaccine - Micromet

Latest Information Update: 29 Mar 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Amgen; Center of Molecular Immunology
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 02 Mar 2012 No development reported - Preclinical for Cancer in North America (unspecified route)
  • 13 Aug 2009 SAI-TGF-alpha is available for licensing or purchase (http://www.micromet.de)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top